Lipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats

Lipids in Health and Disease

Volumn 14, Issue 1, 2015, Pages

  Ning, Conghua ^a   Liu, Lina ^a   Lv, Guodong ^a   Yang, Ye ^a   Zhang, Yuanyuan ^a   Yu, Rui ^a   Wang, Yongtao ^a   Zhu, Jun ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes induced liver injury; NF B; PPAR ; Vitamin D

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CHOLESTEROL; COLECALCIFEROL; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHORUS; TRANSFORMING GROWTH FACTOR BETA1; CARNITINE PALMITOYLTRANSFERASE; CCL2 PROTEIN, RAT; VITAMIN D;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HEPATITIS; IMMUNOHISTOLOGY; LIPID METABOLISM; LIVER WEIGHT; MALE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; BLOTTING, WESTERN; CARNITINE O-PALMITOYLTRANSFERASE; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LIPID METABOLISM; LIVER; MALE; NF-KAPPA B; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D;

EID: 84928471724     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-015-0030-5     Document Type: Article

References (49)

1. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol. 2006;40:68-76.
2. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756-61.
3. Manna P, Das J, Ghosh J, Sil PC. Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid. Free Radic Biol Med. 2010;48:1465-84.
4. Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266-81.
5. Holick MF. Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets. 2011;12:4-18.
6. James WP. 22nd Marabou Symposium: the changing faces of vitamin D. Nutr Rev. 2008;66:286-90.
7. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10:185-97.
8. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-37.
9. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97:93-101.
10. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol. 2007;8:285-93.
11. Harris SS. Does vitamin D deficiency contribute to increased rates of cardiovascular disease and type 2 diabetes in African Americans? Am J Clin Nutr. 2011;93:1175S-8.
12. Ganji V, Zhang X, Shaikh N, Tangpricha V. Serum 25-hydroxyvitamin D concentrations are associated with prevalence of metabolic syndrome and various cardiometabolic risk factors in US children and adolescents based on assay-adjusted serum 25-hydroxyvitamin D data from NHANES 2001-2006. Am J Clin Nutr. 2011;94:225-33.
13. Anagnostis P, Athyros VG, Adamidou F, Florentin M, Karagiannis A. Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk? Curr Vasc Pharmacol. 2010;8:720-30.
14. Zhang C, Lu X, Tan Y, Li B, Miao X, Jin L, et al. Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model. PLoS One. 2012;7, e49257.
15. Boden G, She P, Mozzoli M, Cheung P, Gumireddy K, Reddy P, et al. Free fatty acids produce insulin resistance and activate the proinflammatory nuclear factor-kappaB pathway in rat liver. Diabetes. 2005;54:3458-65.
16. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant. 2006;21:889-97.
17. Allison J, Thomas H, Beck D, Brady JL, Lew AM, Elefanty A, et al. Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction. Int Immunol. 2000;12:9-17.
18. Abdelmegeed MA, Yoo SH, Henderson LE, Gonzalez FJ, Woodcroft KJ, Song BJ. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. J Nutr. 2011;141:603-10.
19. Motiwala SR, Wang TJ. Vitamin D and cardiovascular risk. Curr Hypertens Rep. 2012;14:209-18.
20. Zittermann A, Frisch S, Berthold HK, Gotting C, Kuhn J, Kleesiek K, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89:1321-7.
21. Lee TI, Kao YH, Chen YC, Tsai WC, Chung CC, Chen YJ. Cardiac metabolism, inflammation, and peroxisome proliferator-activated receptors modulated by 1,25-dihydroxyvitamin D3 in diabetic rats. Int J Cardiol. 2014;176:151-7.
22. Jablonski KL, Jovanovich A, Holmen J, Targher G, McFann K, Kendrick J, et al. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013;23:792-8.
23. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J. 2013;60:743-52.
24. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care. 2004;27:2498-500.
25. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54:3541-6.
26. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, et al. Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest. 2006;29:55-60.
27. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev. 2007;28:365-86.
28. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405-55.
29. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-βand NF-κB. Nat Med. 2005;11:183-90.
30. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116:1494-505.
31. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol. 2002;13:894-902.
32. Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol. 2008;28:2195-201.
33. Tous M, Ferre N, Rull A, Marsillach J, Coll B, Alonso-Villaverde C, et al. Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochem Biophys Res Commun. 2006;340:1078-84.
34. Kassel KM, Guo GL, Tawfik O, Luyendyk JP. Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionine-choline-deficient diet. Lab Invest. 2010;90:1794-804.
35. Gregoire FM, Zhang Q, Smith SJ, Tong C, Ross D, Lopez H, et al. Diet-induced obesity and hepatic gene expression alterations in C57BL/6 J and ICAM-1-deficient mice. Am J Physiol Endocrinol Metab. 2002;282:E703-13.
36. Watanabe N, Shikata K, Shikata Y, Sarai K, Omori K, Kodera R, et al. Involvement of MAPKs in ICAM-1 expression in glomerular endothelial cells in diabetic nephropathy. Acta Med Okayama. 2011;65:247-57.
37. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 2002;7:d793-807.
38. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-8.
39. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 1985;316:701-5.
40. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006;10:76-99.
41. Salum E, Kampus P, Zilmer M, Eha J, Butlin M, Avolio AP, et al. Effect of vitamin D on aortic remodeling in streptozotocin-induced diabetes. Cardiovasc Diabetol. 2012;11:58.
42. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-80.
43. Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004;61:393-416.
44. Yi Y, Yu Z e, Min X, Luo X q, Lu X f, Wenhua L. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. Eur J Clin Invest. 2012;42(11):1189-96.
45. Yi Y, Yu Z e, Min X, Luo X q, Lu X f, Wenhua LingRao MS, et al. PPARalpha in the pathogenesis of fatty liver disease. Hepatology. 2004;40:783-6.
46. Chen WL, Chen YL, Chiang YM, Wang SG, Lee HM. Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARalpha/AMPK/FoxO1/ATGL pathway. Biochem Pharmacol. 2012;84:522-31.
47. Videla LA, Pettinelli P. Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity. PPAR Res. 2012;2012:107434.
48. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996;384:39-43.
49. Delerive P, De Bosscher K, Besnard S, Vanden BW, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048-54.